TABLE 11.
Cohorta | Dose in mg (no. of capsules) | No. of participants (active/placebo) |
---|---|---|
A | 7.5 (1) | 6/2 |
B | 15 (2) | 6/2 |
C | 30 (4) | 6/2 |
Da | 30 (4) | 12/2 |
E | 60 (8) | 6/2 |
Fa | 60 (8) | 12/2 |
Cohorts D and F, which involved a BAL procedure, were dosed after assessing the tolerability of the 30- and 60-mg dose, respectively, in cohorts C and E.